1 / 51

LINEE GUIDA SULLA NIV : COME E PERCHE’

Rehab:give a chance to dyspnea. LINEE GUIDA SULLA NIV : COME E PERCHE’. Dott. M Vitacca FERS Divisione di Pneumologia ICS S.Maugeri IRCCS Lumezzane (BS) Italy. IDENTIFY PATIENTS (according to location ?). 1. Clinical abnormalities - moderate to severe dyspnea

bjeremy
Télécharger la présentation

LINEE GUIDA SULLA NIV : COME E PERCHE’

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Rehab:give a chance to dyspnea LINEE GUIDA SULLA NIV : COME E PERCHE’ Dott. M Vitacca FERS Divisione di Pneumologia ICS S.Maugeri IRCCS Lumezzane (BS) Italy

  2. IDENTIFY PATIENTS (according to location ?) 1. Clinical abnormalities - moderate to severe dyspnea - RR > 24 b/min in COPD - RR > 30 – 35 b/min in AHRF - accessory muscle use, paradoxal breathing 2. Gas exchange abnormalities - PaCO2 > 45 mmHg, pH < 7.35 - PaO2/FiO2 < 250 mmHg Am J Respir Crit Care M d 2001; 163: 283-291; Intensive Care Medicine 2001; 27: 166-178

  3. IL PAZIENTE IPOSSICO

  4. CPAP : Respiratory Effects CPAP intrathoracic alveolar PEEPi pressure pressure compensation Shunt FRC work of breathing Improve gas atelectasis Exchange hypoxemia Pelosi Chest 1996 Pelosi Anesthesiology 1999

  5. Effect of CPAP on lung expansion With CPAP ZEEP

  6. CPAP: Cardiovascular Effects Positive Pressure  ITP  FRC  WOB  LVafterload PTM  PaO2 • Pre-load  Venous return  Cardiac performance  pulmonary congestion

  7. Non invasive CPAP to treat PE or CHF

  8. Non-invasive positive pressureventilation (CPAP orbilevel NPPV) forcardiogenicpulmonaryedema (Cochrane Review) Vital FMR. et al., 2008 endotracheal intubation rate NIV/CPAP vs 02

  9. Prophylaxis in COPDE • Bilevel NIV may increase mortality (RR 1.46, 95% CI 0.64-3.35) • Overall low certainty in evidence

  10. Pre-hospital CPE Intubation Favours NIV “We suggest that CPAP or bilevel NIV be used for patients with acute respiratory failure due to CPE in the pre-hospital setting (conditional recommendation, low certainty of evidence)”

  11. Endotracheal intubation or Non invasive CPAP/PPV to treat Postoperative Hypoxiemic Respiratory Failure ?

  12. Patients scheduled for elective major abdominal surgery (§) and general anesthesia who met a PaO2/FiO2 < 300 after 1 h at 30% (Venturi mask ) in the recovery room. • (§) Opening abdominal wall and viscera exposition > 90 minutes with laparotomic or subcostal incision . Helmet CPAP 10 cmH2O (104 pts) Venturi Mask (105 pts)

  13. Endotracheal intubation or Non invasive CPAP/PPV to treat Hypoxiemic Respiratory Failure (Pneumonia or ARDS) ?

  14. Frat JP, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015;372:2185–2196. NIV (full face mask) was compared with high-flow nasal oxygen (HFNO) and standard oxygen in a three-way randomized controlled trial on patients with ARDS (PaO2/FIO2, 300). Although the main outcome, intubation rate, was not different in the whole cohort, it was significantly lower with HFNO in the subgroup with PaO2/FIO2 less than 200.

  15. Keenan SP, et al.; Canadian Critical Care Trials Group/Canadian Critical Care Society Noninvasive Ventilation Guidelines Group. Clinical practice guidelines for the use of noninvasive positive-pressure ventilation and noninvasive continuous positive airway pressure in the acute care setting. CMAJ 2011;183:E195–E214. Ferguson ND, et al. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med 2012;38:1573–1582. Recent NIV guidelines have made no recommendation for NIV use in acute lung injury or pneumonia or have suggested its use only for mild ARDS !

  16. ARDS task force : Intensive Care Med. 2012 Oct;38(10):1573-82.

  17. RECOMANDATIONS • Continuoustreatments (better with helmet) with adequate peep (>10) and low PS. • HFNC may help but the best balance between the techniquesisunknown. • Do not delay intubationif: P/F ratio after 1 hour < 140 – 170 Vt>9.5 ml/kg PBW HACOR score>5 Especiallyif SAPSII>34 or SOFA>6

  18. Recommendation Given the uncertainty of evidence we are unable to offer a recommendation on the use of NIV for de novo ARF !!! Justification …NIV use led to a decrease in mortality …and the need for intubation , low certainty of evidence... The overall effect in the studies is positive on this end-point, but not for other end-points such as mortality. … There is not enough evidence to recommend its use. …a trial of NIV might be offered to a patient with hypoxaemic respiratory failure, community-acquired pneumonia or early ARDS …. experienced clinical team, Careful selection are close monitoring in the ICU, reassessed early intubate promptly if they are not improving.

  19. IL PAZIENTE IPERCAPNICO

  20. 1.0 0 > flow RESISTANCES V’ (L/m) Pdi (cmH2O) 40 0 PTP-PEEPidyn PTP-res + PTP-el excessive loading HYPERINFLATION (High PEEPi-dyn), COPD > 40%

  21. AJRCCM 164:638-42,2001

  22. PRINCIPALI CRITICITA’ 1. Potenzialeimpatto del ritardo di applicazione NIV dopoilricovero: 232 H units for 9716 patients, 1678 (20%) on admission were acidotic and 6% became acidotic later. in pz con la peggioreacidosiall’ingresso(GR1), dopo 1 h <50% NIV, 30% dopointervallo di almeno 3 h In pazienti GR2 (acidosipeggiorata al 2° controllo) <25% NIV in 1 h e 48% a 3 h 1077 patients received NIV (11%), 55% had a pH <7.26 30% patients with persisting respiratory acidosis did not receive NIV. 2. Indicazionialla NIV e mortalità: Hospital mortality was 25% for patients receiving NIV but 39% for those with late onset acidosis. 34% deipz con ph 7,26-7,35 non hannoricevuto NIV, 18% di questisonomorti 3. Mancanza di un action plan: 12% deicasitrattati con NIV (chesono poi deceduti) senza action plan in caso di fallimentodella NIV

  23. Prophylaxis in COPDE “We suggest NIV not be used in patients with hypercapnia who are not acidotic in the setting of a COPD exacerbation (conditional recommendation, low certainty in the evidence)”

  24. COPD Patient selection Chronic obstructive pulmonary disease (COPD) • Optimal medical therapy, target SpO2 88 – 92% (Grade A) • Start NIV when pH < 7.35 and PaCO2 > 45 mm Hg (Grade A) • Severe acidosis pH < 7.25 does not preclude a trial of NIV (Grade B) • The use of NIV should not delay invasive ventilation when this is more appropriate (Grade C) • The practice of NIV should be regularly audited to maintain standards (Grade C)

  25. COPD - Mortality

  26. COPD Other Outcomes • Intubation • RR 0.41 (95% CI 0.33-0.52) – high certainty • Nosocomial Pneumonia • RR 0.26 (95% CI 0.08-0.81) – low certainty

  27. COPD: New from Previous Guidelines “We recommend a trial of bilevel NIV in patients considered to require ETI and mechanical ventilation, unless the patient is immediately deteriorating (strong recommendation, moderate certainty in the evidence)”

  28. Others conditions

  29. Pandemic Viral Illness • Mortality – Observational studies only

  30. Pandemic Viral Illness • No RCTs • Heterogeneous group of patients • Low event numbers (++imprecision) • ?transmission risk with NIV “Given the uncertainty of evidence we are unable to offer a recommendation for this question”

  31. Chest Trauma • Heterogenous population • Severity of illness, rib # vs flail chest, other injuries • Various comparators • Supplemental oxygen vs invasive ventilation “We suggest NIV for chest trauma patients with ARF. (Conditional recommendation, moderate certainty of evidence)”

  32. Other patients with airways disease Asthma • NIV should not be used in patients with acute asthma exacerbations and hypercapnic respiratory failure (Grade C) • Acute episodes of hypercapnia may complicate chronic asthma. This condition closely resembles COPD and should be managed as such (Grade D) Bronchiectasis • Controlled oxygen therapy should be used (Grade D) • NIV should be started in AHRF using the same criteria as in COPD (Grade B) • NIV ventilation should usually be tried before resorting to IMV in those with less severe physiological disturbance (Grade C)

  33. Extra pulmonary restrictive disorders Restrictive lung diseases - neuromuscular disorders (NMD) and chest wall deformity (CWD) • Controlled oxygen therapy should be used (Grade D ) • NIV should almost always be trialled in the acutely unwell patients with NMD or CWD with hypercapnia. Do not wait for acidosis to develop (Grade D) • In patients with NMD or CWD NIV should be considered in acute illness when vital capacity is known to be less than 1 litre and respiratory rate greater than 20 even if normal PaCO2 (Grade D) Obesity hypoventilation syndrome (OHS) • Controlled oxygen therapy should be used (Grade D) • Same criteria for initiation of NIV should be used as in AECOPD (Grade B) • NIV is indicated in some hospitalized OHS hypercapnic patients with symptoms even in the absence of acidosis (Grade D)

  34. the correct time to stop

  35. WEAK COUGH AND HYPER-SECRETIONS • SEVERE ENCEPHALOPATHY • INTOLERANCE AND AGITATION • PATIENT-VENTILATORY ASYNCHRONIES • EXCESSIVE LEAKS • DISCOMFORT • SLEEP DISTURBANCES • HYPERGLICAEMIA • LOW ADLs • POOR RESPONSE OF ABG AND RR • HIGH SCORES OF SEVERITY OF ILLNESS NEED OF ETI: range → 5-60% Courtesy of dott Scala

  36. La giusta location

  37. Timing is all… • Start early but not too early (Barbe study) • You are too late if… • Pt on verge of respiratory arrest • Pt severely hypoxaemic (PaO2/FiO2 < 75) • Pt comatose or hugely agitated • Medically unstable: acute MI, GI bleed, shock • What is your unit’s ‘door to mask’ time? • What are the main limitations? Simonds ERS school

  38. Il training adeguato

  39. Monitoraggio

  40. Ventilatory Monitoring • Respiratory pattern • Pt-ventinteraction • Availabilityof ETI • in case of NIV failure Courtesy of dott Scala

  41. Am J RespirCrit Care Med. 2001 Feb;163(2):540-77 Almost all the side effects of NIV are due to problems with interfaces

  42. Interface rotation strategy Conti G et al. RespirMed 2007; 52:1463-71 Girault C et al. Crit Care Med 2009; 37:124-31 Courtesy of dott Scala

  43. Use of NIV for Bronchoscopy • RCT: Bilevel NIV better at oxygenation and hemodynamics than standard O2 • Antonelli M et al, Chest 2002 • RCT: CPAP better at avoiding gas exchange abn or intub than std O2 • Maitre B et al, AJRCCM 2000 • RCT: NIV > HFNT at avoiding desats • Simon M et al, Crit Care 2014 • Bilevel or CPAP “could be considered”

  44. Palliative Care • NIV in patients with respiratory failure receiving palliative care? • NIV improved dyspnea – lowered Borg scale by 0.89 points (95% CI 0.79-0.99) • NIV decreased opioid requirement – 32.4mg less morphine equivalents (95% CI 17.4-47.4) “We suggest offering NIV to dyspnoeic patients for palliation in the setting of terminal cancer or other terminal conditions. (Conditional recommendation, moderate certainty of evidence)”

  45. Conclusion 1 • Caution to use NIV in patients with «de novo» ARF • NIV in patients with ARF and COPD even in case of hypercapnic coma • I intubate my patient without delay when he meets criteria for intubation (RR > 40 under NIV, hemodynamic instability…) • 4. In patients with chronic lung disease and with persistent respiratory failure (RR >30 and pH < 7.30), I don’t extend NIV beyond 3-12 h (?)

  46. Conclusion 2 1. on ventilators: Good screen with clear traces Algorythm able to depict the presence of asynchrony and warn the clinicians 2. Non-invasive monitoring of gas exchange during NIV 3. sleep architecture monitoring

More Related